Naomi Hunder, M.D., is Silverback’s chief medical officer. Dr. Hunder previously served as vice president, head of the clinical development and medical affairs groups at Acerta Pharma. As the global clinical lead for acalabrutinib, she oversaw US approval, designed the lifecycle strategy, and built the medical affairs function to support global launches, including initiation of a broad investigator sponsored trial program. Before joining Acerta, Dr. Hunder was vice president of clinical development at Seattle Genetics, where she was the therapeutic area lead for lymphoma and myeloma. She served as the clinical development lead for brentuximab vedotin, worked with the alliance partner on global registrations, and led the company’s first Phase 3 trial, which confirmed the original accelerated approval. Prior to Seattle Genetics, Dr. Hunder held a position at ZymoGenetics developing cytokines for oncology and viral hepatitis. A board certified medical oncologist, Dr. Hunder received her M.D. from Jefferson Medical College and her Internal Medicine training at the University of Pennsylvania. She completed her oncology fellowship training at Fred Hutchinson Cancer Research Center/University of Washington.